XML 53 R38.htm IDEA: XBRL DOCUMENT v3.22.1
SHAREHOLDERS' EQUITY (Tables)
12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement, Noncash Expense [Abstract]  
Summary of Stock Options Granted

2.The following table summarizes the activities for the Company’s stock options for the year ended December 31, 2021:

 

Year ended

December 31, 2021

 

Number

of options

Weighted

average

exercise

price

Weighted

average

remaining

contractual

term

(in years)

Aggregate

intrinsic

value

 

Outstanding at beginning of year

6,238,729

$

3.52

3.17

$

2,654

Granted

1,902,868

3.72

Exercised

(2,098,957

)

2.25

Forfeited or expired

(856,194

)

7.75

 

Outstanding at end of the year

5,186,446

$

3.40

4.01

$

534

 

Options exercisable at end of the year

2,342,399

$

3.57

2.75

$

370

 

Vested and expected to vest

4,664,666

$

3.41

3.87

$

508

Schedule of RSUs Granted

The following table summarizes the activities for the Company’s RSUs for the year ended December 31, 2021:  

Year ended

December 31, 2021

Number of

RSUs

Aggregate

intrinsic

value

 

Unvested at beginning of year

309,986

$

862

Granted

588,466

Vested

(129,380

)

Forfeited

(69,393

)

 

Unvested at end of the year

699,679

$

1,805

 

Vested and expected to vest

493,881

$

1,274

Summary of Stock Options And RSUs Granted Separated Into Ranges of Exercise Price

The following is a summary of the Company’s stock options and RSUs granted separated into ranges of exercise price:

Exercise price

(range)

 

 

Options and RSUs

outstanding

as of

December 31, 2021

 

 

Weighted

average

remaining

contractual

life (years) for outstanding

options

 

 

Weighted

average

exercise

price

 

 

Options and RSUs

exercisable

as of

December 31, 2021

 

 

Weighted

average

remaining contractual life

(years) for exercisable

options

 

 

Weighted

average

exercise

price

$

 

 

 

 

 

 

 

 

$

 

 

 

 

 

 

 

 

$

 

RSUs 0.0

699,679

-

0.00

-

-

0.00

0.01-2.00

154,389

1.17

1.45

141,239

0.92

1.42

2.01-4.00

4,460,682

4.39

3.05

1,760,845

3.35

2.78

4.01-6.00

281,375

3.31

4.41

150,315

1.80

4.57

6.01-8.00

15,000

0.75

6.21

15,000

0.75

6.21

8.01-10.00

275,000

0.40

9.00

275,000

0.40

9.00

 

5,886,125

2,342,399

Schedule of Equity-Based Compensation Expense

The total equity-based compensation expense related to all of the Company’s equity-based awards, recognized for the years ended December 31, 2019, 2020 and 2021, was comprised as follows:

Year ended

December 31,

2019

2020

2021

 

Cost of revenues

$

71

$

110

$

289

Research and development, net

366

243

236

Sales and marketing

708

545

700

General and administrative

908

764

1,337

 

Total share-based compensation expenses

$

2,053

$

1,662

$

2,562